ClinicalTrials.gg
CompletedNCT02795260Updated Oct 1, 2020

Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)

A Phase 3 interventional study of Bacillus Calmette - Guerin and placebo of Bacillus Calmette - Guerin in Tuberculosis, sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. Completed. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-01.

Sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (part of Chongqing Zhifei Biological Products Co., Ltd.) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,802
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing BCG Vaccine in Tuberculosis — 2 open to participants now, 4 under way, none of them phase 3. BCG Vaccine · Tuberculosis.

Enrollment
4th of 20
1,802 · median 38
Started
2016
with 1 other
Phase 3
2 of 20
none open now
Registered
11th of 20
by date
Lead sponsor
2 of 20
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Among the 20 studies testing BCG Vaccine in Tuberculosis, this one is the 4th largest by enrollment, is one of 2 that started in 2016, is one of 2 in phase 3, and was the 11th registered.

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

2 of the 20 studies testing BCG Vaccine in Tuberculosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About BCG Vaccine

BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing BCG Vaccine in Tuberculosis, or all of them as a file.
02

Study summary

The investigators recruit about 1800 cases participants who has signed ICF,then do some physical examinations for these people, including ecg, X-ray, HIV,blood pressure, specific gamma-interferon detection ,collection of medical history and the like .These subjects who meet the standard are considered as study population I. Population I are injected intradermally with ESAT6-CFP10 and Tuberculin purified protein derivative(TB-PPD) at different arm of the same subject and get at least 360 participants whose three kinds of detection result are all negative and are considered as study population II.Then,they are immune to the Bacillus Calmette -Guerin(BCG) vaccine or the placebo of the BCG.Do specific gamma-interferon detection before the skin test,then inject intradermally with ESAT6-CFP10 and TB-PPD at different arm of the same subject 12 weeks after immunity.

Read the detailed description

The investigators recruit about 1800 cases participants who has signed ICF,then do some physical examinations for these people, including ecg, X-ray, HIV,blood pressure, specific gamma-interferon detection(γ-IFN) ,collection of medical history and the like .These subjects who meet the standard are considered as study population I. Population I are injected intradermally with ESAT6-CFP10 and Tuberculin purified protein derivative(TB-PPD) at different arm of the same subject and get at least 360 participants whose three kinds of detection result are all negative(specific gamma-interferon detection ,TB-PPD and ESAT6-CFP10 ) and are considered as study population II.Then,they are immune to the Bacillus Calmette -Guerin(BCG) vaccine or the placebo of the BCG(BCG and the palcebo ratio of 2:1 ),they are incorporated into the Population III. Do specific gamma-interferon detection before the skin test,then inject intradermally with ESAT6-CFP10 and TB-PPD at different arm of the same subject 12 weeks after immunity. Evaluate the specificity of the ESAT6-CFP10 allergen by negative coincidence rate for BCG vaccinated crowd ,and the safety of ESAT6-CFP10 in all participant,and the correlation between ESAT6-CFP10 ,TB-PPD and γ-IFN.

03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • ESAT6
  • CFP10
  • skin test
  • diagnostic test
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria of the screening crowd

  1. 18-65 years old;
  2. consent and signed form;
  3. comply with follow-up;
  4. No history of tuberculosis;
  5. Physical condition:no obvious heart,liver,kidney, digestive tract,nervous system,mental disorder from signed informed consent to the injection;
  6. Normal axillary temperature (quiet condition blow 37.0℃)
  7. No abnormal chest by X-ray check;

Exclusion Criteria of the screening crowd

  1. Has the following serious disease, such as advanced cancer, diabetes, (copd) in acute episodes, acute/ progressive liver disease or kidney disease, congestive heart failure, etc;
  2. Epilepsy and psychiatric patients
  3. Has known or suspected (or risk possible) immune damaged or abnormal functional , accept and or immunopotentiator treatment, outside the gastrointestinal tract protein or blood products or plasma extraction in 3 months;
  4. Has acute febrile diseases and infectious diseases;
  5. taking part in any other new drug clinical trials or participated in any other new drug clinical trials within 3 months before this trials;
  6. a clear history of drug allergy ;
  7. In pregnancy or lactation;
  8. There is a clear history of high blood pressure and systolic blood pressure ≥180mmHg , and/or diastolic blood pressure of ≥ 100mmHg after drug control ;
  9. Researchers consider that any conditions may affect the trial evaluation.

Inclusion Criteria of three negative crowd

  1. conforming to the inclusion criteria of the screening crowd ;
  2. the result of four detection methods are all the negative: ESAT6-CFP10 、 TB - PPD and specific gamma - IFN and ;

Exclusion Criteria of three negative crowd

  1. conforming to the exclusion criteria of the screening crowd ;
  2. With BCG vaccination taboo .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,802 participants (actual)

Study arms

  • Experimental
    ESAT6-CFP10 in the right arm

    Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of BCG immunization :ESAT6-CFP10 in the right arm and TB-PPD in the left arm concomitantly,according to a randomisation scheme.

    Biological: Bacillus Calmette - Guerin · Biological: placebo of Bacillus Calmette - Guerin

  • Experimental
    ESAT6-CFP10 in the left arm

    Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of Bacillus Calmette - Guerin immunization :ESAT6-CFP10 in the left arm and TB-PPD in the right arm concomitantly,according to a randomisation scheme.

    Biological: Bacillus Calmette - Guerin · Biological: placebo of Bacillus Calmette - Guerin

Interventions

  • The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .

    Also known as: BCG

  • Biologicalplacebo of Bacillus Calmette - Guerin

    The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .

    Also known as: placebo of BCG

06

What researchers measure

Primary outcomes

  1. Number of study population III Negative for Reaction at 24 hours After intradermal injection with EC or TB-PPD

    Time frame: At 24 hours after Intradermal injection with EC or TB-PPD

  2. Number of study population III Negative for Reaction at 48 hours After intradermal injection with EC or TB-PPD

    Time frame: At 48 hours after Intradermal injection with EC or TB-PPD

Secondary outcomes

  1. the number of participants with Adverse Events after Intradermal injection

    Time frame: within 48 hours after after Intradermal injection

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ravn P, Munk ME, Andersen AB, Lundgren B, Lundgren JD, Nielsen LN, Kok-Jensen A, Andersen P, Weldingh K. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol. 2005 Apr;12(4):491-6. doi: 10.1128/CDLI.12.4.491-496.2005. PubMed 15817755 ↗
  • Brusasca PN, Colangeli R, Lyashchenko KP, Zhao X, Vogelstein M, Spencer JS, McMurray DN, Gennaro ML. Immunological characterization of antigens encoded by the RD1 region of the Mycobacterium tuberculosis genome. Scand J Immunol. 2001 Nov;54(5):448-52. doi: 10.1046/j.1365-3083.2001.00975.x. PubMed 11696195 ↗
  • Weldingh K, Andersen P. ESAT-6/CFP10 skin test predicts disease in M. tuberculosis-infected guinea pigs. PLoS One. 2008 Apr 23;3(4):e1978. doi: 10.1371/journal.pone.0001978. PubMed 18431468 ↗
  • Aagaard C, Govaerts M, Meikle V, Vallecillo AJ, Gutierrez-Pabello JA, Suarez-Guemes F, McNair J, Cataldi A, Espitia C, Andersen P, Pollock JM. Optimizing antigen cocktails for detection of Mycobacterium bovis in herds with different prevalences of bovine tuberculosis: ESAT6-CFP10 mixture shows optimal sensitivity and specificity. J Clin Microbiol. 2006 Dec;44(12):4326-35. doi: 10.1128/JCM.01184-06. Epub 2006 Sep 27. PubMed 17005738 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2016
First posted
Jun 10, 2016
Start
May 2016
Primary completionActual
Oct 2016
CompletionActual
Oct 2016
Last update
Oct 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02795260
Collaborators
Air Force Military Medical University, China, Proswell Medical Corporation, Jiangsu Province Centers for Disease Control and Prevention, Jurong Centers for Disease Control and Prevention
Responsible party
Sponsor
First posted
Jun 10, 2016
Start date
May 2016
Primary completion
Oct 2016
Completion
Oct 2016
Last update
Oct 1, 2020

Study contacts

Wei Lu, Master
principal investigator · Jiangsu Province Centers for Disease Control and Prevention

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BCG Vaccine

Start the discussion